Plain-English translation of NCT05080998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is validating a urine test called CxBladder Monitor (and a newer version called CxBladder Monitor Plus) to see how well it can detect when bladder cancer comes back in patients who have already been diagnosed. Researchers want to compare the results of this urine test against the standard way doctors currently check for recurrence — a procedure called cystoscopy combined with tissue analysis.
Currently, detecting bladder cancer recurrence requires an invasive procedure. If this urine test proves accurate and reliable, it could offer patients a simpler, less invasive way to monitor for cancer recurrence during their follow-up care.
You likely qualify if…
You likely don't qualify if…
You will attend 4 surveillance visits at a participating medical center over several months. At each visit, you will provide a urine sample, which will be tested with the CxBladder urine test and also sent for standard laboratory analysis. You will continue your regular surveillance care as planned — including cystoscopy and other monitoring your doctor recommends. The study team will collect tissue samples if available from your original cancer diagnosis and any recurrences that occur during the study to help understand the test's accuracy.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States